文献速递肝病消化道肿瘤与早癌

AFP模型在因肝细胞癌接受肝移植的病毒性肝炎相关肝硬化患者中预测肿瘤复发的验证

Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
PubMed 文献 · J Hepatol · 2016-11-27

在四个意大利中心574例因肝细胞癌接受肝移植的患者中验证AFP模型。AFP评分>2者五年复发概率显著高于≤2者,全人群为49.8%对13.2%(HR=4.98),且AFP评分较米兰标准显著改善无复发预测。结论认为AFP评分可用于病毒性肝炎相关肝硬化高发人群中肝细胞癌候选者的筛选。

要点

  • AFP评分>2者五年复发概率在全人群为49.8%,显著高于≤2者的13.2%(HR=4.98)。
  • 在米兰标准内和超出米兰标准的患者中,AFP评分>2均与更高的复发风险相关。
  • AFP评分>2者五年总生存率为42.2%,低于≤2者的71.7%(HR=2.14)。

核心结论

  • AFP模型可识别复发低风险的肝细胞癌候选者,包括部分被米兰标准排除在外的患者。
  • 在病毒性肝炎相关肝硬化占多数的肝细胞癌人群中,AFP评分可用于筛选肝移植候选者。

研究设计与样本

  • 在四个意大利中心接受肝移植的574例肝细胞癌患者中验证AFP模型。
  • AFP评分在肝移植前最后一次评估时计算。
  • 采用log-rank检验或竞争风险分析估计复发和生存概率,并按AFP模型进行比较。

主要发现

  • 全人群中AFP评分≤2与>2的五年复发概率分别为13.2±1.8%与49.8±8.7%(p<0.001,HR=4.98)。
  • 米兰标准内患者中AFP评分≤2与>2的五年复发概率分别为12.8±2.0%与32.4±12.1%(p=0.009,HR=3.51)。
  • 超出米兰标准患者中AFP评分≤2与>2的五年复发概率分别为14.9±4.2%与58.9±11.5%(p<0.001,HR=4.26)。
  • HCV患者中AFP评分≤2与>2的五年复发概率分别为14.9±2.5%与67.6±14.7%(p<0.001,HR=6.56);HBV患者中分别为11.6±3.4%与34.3±12.5%(p=0.012,HR=3.49)。
  • AFP评分≤2与>2的五年总生存率分别为71.7±2.2%与42.2±8.3%(p<0.001,HR=2.14)。

关键数值与推荐

  • AFP评分>2较≤2的五年复发风险更高,全人群HR=4.98,米兰标准内HR=3.51,超出米兰标准HR=4.26,HCV患者HR=6.56,HBV患者HR=3.49。
  • AFP评分>2较≤2的五年总生存风险更高,HR=2.14。
  • AFP评分较米兰标准显著改善了对无复发的预测(净重分类改善分析)。

临床怎么用

  • 作者认为AFP评分可被提议用于病毒性肝炎或HCV相关肝硬化占比较高的项目中筛选肝细胞癌候选者。
  • 作者指出AFP评分已被法国器官分配组织正式采纳用于肝细胞癌患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The AFP model was shown to be superior to the Milan criteria for predicting hepatocellular carcinoma (HCC) recurrence after liver transplantation in a French population. Our aim was to test the AFP model in a non-French, post-hepatitic cirrhosis-based population of HCC candidates. METHODS: 574 patients transplanted for HCC in four Italian centers were studied. AFP score was assessed at the last evaluation before liver transplantation (LT). Probabilities of recurrence and survival were estimated by the log-rank test or competing risk analysis and compared according to the AFP model. RESULTS: 24.7% patients were beyond Milan criteria. HCC complicated hepatitis C virus (HCV) and hepatitis B virus (HBV) cirrhosis in 58.7% and 24% of the cases, respectively. Five-year probabilities of recurrence differed according to AFP score ⩽2 vs. >2 in the whole population (13.2±1.8% vs. 49.8±8.7%, p<0.001, HR=4.98), in patients within Milan criteria (12.8±2.0% vs. 32.4±12.1%, p=0.009, HR=3.51), beyond Milan criteria (14.9±4.2% vs. 58.9±11.5%, p<0.001, HR=4.26), HCV patients (14.9±2.5% vs. 67.6±14.7%, p<0.001, HR=6.56) and HBV patients (11.6±3.4% vs. 34.3±12.5%, p=0.012, HR=3.49). By net reclassification improvement analysis AFP score significantly improved prediction of non-recurrence compared to Milan criteria. Overall five-year survival rates according to AFP score ⩽2 or >2 were 71.7±2.2% vs. 42.2±8.3% (p<0.001, HR=2.14). CONCLUSIONS: The AFP model identifies HCC candidates at low risk of recurrence, otherwise excluded by Milan criteria in a population with a predominance of post-hepatitic-related HCC. The AFP score can be proposed for selection of HCC candidates in programs with a high proportion of viral/HCV-related cirrhosis. LAY SUMMARY: Selection criteria for liver transplantation of patients affected with hepatocellular carcinoma (HCC) are based on the Milan criteria, which have been shown to be too restrictive, precluding access to liver transplantation for some patients who might be cured by this operation. Recently, a French group of researchers developed a new selection model called the AFP model, or AFP score, allowing some patients with HCC not meeting Milan criteria to be transplanted with excellent results. In the present work, the AFP score was tested in a population of non-French patients transplanted for HCC occurring mainly on post-hepatitic (HCV or HBV) cirrhosis. The results confirm that in this specific population, as in the original French population of patients, the AFP model better selects patients with HCC eligible for transplantation, compared to Milan criteria. We conclude that the AFP score, which has been officially adopted by the French organization for Organ Sharing for HCC patients, can also be implemented in countries with an important burden of HCC occurring on post-hepatitic cirrhosis.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Notarpaolo A, Layese R, Magistri P, et al. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. J Hepatol. 2016. PMID: 27899297. doi:10.1016/j.jhep.2016.10.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。